A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

NCT05291234 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease (AD)

Interventions

DRUG: ABBV-916
DRUG: Placebo

Sponsor

AbbVie